ArticleGastroenterology2008
Ovalbumin-protein sigma 1 M-cell targeting facilitates oral tolerance with reduction of antigen-specific CD4+ T cells.
Article in Gastroenterology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 63 citations in OpenAlex.
- Intestinal Microfold Cells Play a Critical Role in the Uptake and Oral Tolerance Mediated by Lysophosphatidylserine-Containing Lipidic Nanoparticles.Nanomaterials (Basel, Switzerland) · 2026Article
- Dietary Antigen Interaction with Intestinal Epithelial Cells.Current allergy and asthma reports · 2026Review
- Early life infection withGut microbes · 2025Article
- Immunostimulatory Pickering emulsion for oral vaccine delivery.International journal of pharmaceutics · 2025Article
- RORγt-APCs: The New Masters of Oral Tolerance.Barrier immunity · 2025Article
- The renaissance of oral tolerance: merging tradition and new insights.Nature reviews. Immunology · 2025Review
- From bench to bedside: an interdisciplinary journey through the gut-lung axis with insights into lung cancer and immunotherapy.Frontiers in immunology · 2024Review
- Recombinant MBP-pσ1 expressed in soybean seeds delays onset and reduces developing disease in an animal model of multiple sclerosis.Plant biotechnology (Tokyo, Japan) · 2022Article
- Mucosal delivery of nanovaccine strategy against COVID-19 and its variants.Acta pharmaceutica Sinica. B · 2022Review
- Oral drug delivery for immunoengineering.Bioengineering & translational medicine · 2022Review
- Intestinal Uptake and Tolerance to Food Antigens.Frontiers in immunology · 2022Review
- Allergic diseases in infancy II-oral tolerance and its failure.The World Allergy Organization journal · 2021Review
- Intestinal Macromolecular Transport Supporting Adaptive Immunity.Cellular and molecular gastroenterology and hepatology · 2019Review
- M Cells: Intelligent Engineering of Mucosal Immune Surveillance.Frontiers in immunology · 2019Review
- Regulatory Immune Mechanisms in Tolerance to Food Allergy.Frontiers in immunology · 2018Review
- Molecular and cellular mechanisms of food allergy and food tolerance.The Journal of allergy and clinical immunology · 2016Review
- From sewer to saviour - targeting the lymphatic system to promote drug exposure and activity.Nature reviews. Drug discovery · 2015Review
- Article
- Peyer's patches and mesenteric lymph nodes cooperatively promote enteropathy in a mouse model of food allergy.PloS one · 2014Article
- Microfold (M) cells: important immunosurveillance posts in the intestinal epithelium.Mucosal immunology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
Abstract
BACKGROUND &
aimsThe follicle-associated epithelium (FAE) plays key roles in antigen uptake and subsequent induction of mucosal immunity. In this study, we examined whether M-cell targeting using a protein antigen (Ag) delivery system would induce oral tolerance instead of enhancement of Ag-specific mucosal antibody (Ab) responses.
methodsMice were fed different doses of a recombinant protein sigma 1 of reovirus genetically conjugated to ovalbumin (OVA-psigma1), psigma1 only, or phosphate-buffered saline (PBS) before oral challenge with OVA plus cholera toxin as mucosal adjuvant. OVA-specific Ab and CD4-positive (CD4(+)) T-cell responses were determined.
resultsA low dose of OVA-psigma1 reduced anti-OVA Ab and CD4(+) T-cell responses in both mucosal and systemic lymphoid tissues. OVA/MHC I-A(d) tetramer staining showed that the numbers of OVA-specific CD4(+) T cells were significantly reduced in lamina propria of mice fed OVA-psigma1 than those fed psigma1 only or PBS only. In fact, Foxp3 expressing CD25(+) CD4(+) T cells were markedly increased in this tissue. Nonetheless, CD25(+) CD4(+) T cells from the spleen, mesenteric lymph nodes, and Peyer's patches of orally tolerized mice showed increased transforming growth factor beta1 (TGF-beta1) and interleukin-10 (IL-10) production compared with nontolerized mice.
conclusionsThese results show that an FAE M-cell targeting protein Ag delivery system facilitates oral tolerance induction because of a reduction in Ag-specific CD4(+) T cells and increased levels of TGF-beta1 and IL-10 producing, CD25(+) CD4(+) regulatory T cells in both systemic and mucosal lymphoid tissues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.